12:00 AM
 | 
Oct 06, 2008
 |  BC Week In Review  |  Company News  |  Other News

Ambrilia cancer, infectious news

Ambrilia restructured and reduced headcount by 14 (33%) to 29 and will look to divest its octreotide (C2L) and goserelin programs before year end....

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >